Loading clinical trials...
Loading clinical trials...
Study of the Relationship Between the Blood Levels of Soluble PDL1 and β2-microglobulin, and the Clinical Course of a Metastatic Solid Tumor Treated With a First-line Therapeutic of Checkpoint Immune Inhibitor
Conditions
Interventions
Blood sample
Locations
1
France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
Start Date
February 10, 2022
Primary Completion Date
February 1, 2024
Completion Date
February 1, 2024
Last Updated
June 22, 2022
NCT07177937
NCT05671510
NCT02621021
NCT03050268
NCT05969860
NCT07540260
Lead Sponsor
University Hospital, Clermont-Ferrand
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions